differences in glp 1 drugs New oral GLP-1 drug delivers up to 12% weight loss 36 weeks The GLP-1 Agonists and Obesity:

But as more patients stay on these medications for yearsnot just monthsquestions around GLP1 longterm safety have become essential to address

Guideline for management of postmeal glucose in diabetes

DPP-4 inhibitor-related pancreatitis: rare but real

Are there alternatives for patients who cant tolerate metformin

Should these trials succeed, they could significantly expand the eligible patient base and therapeutic scope, making GLP-1s a multibillion-dollar drug class across multiple disciplines

To date, tens of thousands of research participants have received GLP-1RAs in RCTs investigating efficacy for improving glycemic control, body weight, and cardiovascular outcomes